Clinical Trial

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2025-01-28; most recent amendment 2026-03-23.
Status change: Not Yet Recruiting → Recruiting 2025-04-07
Status change: Recruiting → Not Yet Recruiting 2025-02-21
Trial Details
NCT Number NCT06799247
Lead Sponsor Cartesian Therapeutics
Conditions Myasthaenia Gravis
Enrollment 100 participants
Start Date 2025-05-06
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-24